ArticleCancer medicine2026

Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post-Progression Outcomes: A Multicenter Real-World Study in Advanced Hepatocellular Carcinoma.

Masanori Inoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.